期刊
EXPERT REVIEW OF RESPIRATORY MEDICINE
卷 5, 期 2, 页码 267-279出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERS.11.18
关键词
diagnosis; pulmonary hypertension; systemic sclerosis; therapy
资金
- NIH/National Heart, Lung and Blood Institute [K23 HL092287, P50 HL084946]
Systemic sclerosis (SSc) is commonly complicated by pulmonary arterial hypertension (PAH), which is a leading cause of death in the SSc patient population. Owing to the fact that the risk of developing pulmonary hypertension is high, screening is important, although the optimal modality remains to be defined. Furthermore, despite recent advances in therapy for PAH, the response to these interventions in patients with PAH with SSc has been discouraging. The lack of clinical response to these therapies may merely reflect the limitations of traditionally employed PAH outcome measures in SSc-PAH patients or highlight the heterogeneity of the disease manifestations within SSc. Importantly, since extrapulmonary involvement of the GI tract and kidneys by SSc limit candidacy for lung transplantation, new therapies that target abnormal cellular proliferation in the pulmonary vasculature are currently under investigation and may be particularly relevant to SSc-PAH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据